CN117427079A - Use of cyano-substituted macrocyclic compounds - Google Patents
Use of cyano-substituted macrocyclic compounds Download PDFInfo
- Publication number
- CN117427079A CN117427079A CN202310893963.8A CN202310893963A CN117427079A CN 117427079 A CN117427079 A CN 117427079A CN 202310893963 A CN202310893963 A CN 202310893963A CN 117427079 A CN117427079 A CN 117427079A
- Authority
- CN
- China
- Prior art keywords
- substance
- formula
- compound
- ros1
- intracranial tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 50
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 238000007917 intracranial administration Methods 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 210000004556 brain Anatomy 0.000 claims description 20
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims description 19
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims description 19
- 206010018338 Glioma Diseases 0.000 claims description 17
- 208000032612 Glial tumor Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- FIKPXCOQUIZNHB-WDEREUQCSA-N repotrectinib Chemical compound C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 101150035397 Ros1 gene Proteins 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000010470 Ageusia Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000019666 ageusia Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000002620 vena cava superior Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 229940121602 repotrectinib Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
The invention discloses an application of a cyano-substituted macrocyclic compound. The invention provides application of a substance A in preparation of medicines, wherein the substance A is a compound shown as a formula I or pharmaceutically acceptable salt thereof; the medicine is used for treating and/or preventing intracranial tumor; the compound shown as the formula I has high safety in treating and/or preventing intracranial tumors.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of a cyano-substituted macrocyclic compound.
Background
Gliomas (glioma), also known as gliomas, are the most common primary central nervous system tumors, accounting for about half of all intracranial primary tumors. Glioma is a primary tumor of the central nervous system with highest morbidity (annual morbidity is about 3-8 people/10 ten thousand people) and mortality (survival rate of less than 3% -7% in 5 years). Glioma patients may develop symptoms such as headache, personality changes, nausea, stroke-like symptoms, etc., and symptoms often develop rapidly, and severe patients may develop confusion. Gliomas generally recur under full force therapy, with typical survival times of 12-15 months after diagnosis. In untreated cases, the survival is short, typically only 3 months.
All current clinical ROS1 inhibitors are multi-kinase inhibitors, with strong inhibition of ALK and/or Trk kinase, but no highly selective inhibition of ROS 1. Clinically, ALK inhibitors are generally proved to have toxic and side effects related to targets such as pulmonary toxicity (e.g. interstitial lung disease), trk inhibitors are generally proved to have toxic and side effects related to targets such as abnormal taste, cognitive dysfunction, dizziness, ataxia, weight gain, mood disorder, sleep disorder, pain after drug withdrawal and the like (Liu D, flory J, lin A, et al, research of on-target adverse events caused by TRK inhibitor therapy.Annals of oncology.2020,31 (9): 1207-1215). Entritinib has a strong inhibitory effect on Trk kinase, and in STARTRK (355 patients) clinical trials, there are a number of neurological related side effects, the most common of which include loss of taste (44%), dizziness (38%), dysesthesia (34%), cognitive impairment (27%), etc., where more than three levels of cognitive impairment are reached (4.5%) (https:// www.accessdata.fda.gov/drug sada_docs/label/2019/212720 s000lbl. Similar to Entritinib, TPX-0005 in TRIDENT-1 clinical trials, the most common side effects were dizziness (62%) and loss of taste (33%), etc. (B.C.Cho et al MA11.07 Phase 1/2TRIDENT-1Study of Repotrectinib in Patients with ROS1+or NTRK+Advanced Solid Tumors,Journal of Thoracic Oncology Vol.16No.3S). For patients with ROS1 gene fusion, in addition to target-related side effects, additional side effects due to off-target are required, which can affect the therapeutic effect and patient experience.
Therefore, for clinical treatment of ROS1 gene fusion glioma, there is an urgent need for an effective compound that can reduce the side effects of drugs.
Disclosure of Invention
The invention aims to solve the technical problem that the existing medicament for treating ROS1 fusion intracranial tumor has strong side effect. The invention provides application of a cyano-substituted macrocyclic compound, which can treat and/or prevent intracranial tumors. Further, the compounds of the present invention are highly safe for the treatment and/or prevention of intracranial tumors.
The invention provides application of a substance A in preparation of medicines, wherein the substance A is a compound shown as a formula I or pharmaceutically acceptable salt thereof; the medicine is used for treating and/or preventing intracranial tumor;
in such applications, the intracranial tumor can be a ROS1 fused intracranial tumor.
In such applications, the intracranial tumor can be a glioma and/or a non-small cell brain metastasis, such as ROS1 fused glioma or ROS1 fused non-small cell brain metastasis.
In this application, the medicament comprises substance a and a pharmaceutically acceptable carrier.
In such applications, the pharmaceutically acceptable carrier may be a conventional carrier in the art.
In such applications, the frequency of administration of the drug may be 1, 2, or 3 times per day.
In such applications, the medicament may be administered orally.
In such applications, the dosage form of the medicament may be conventional in the art.
In the application, the concentration of the compound shown as the formula I in the medicine can be 0.5-1.5mg/mL; preferably 0.5mg/mL or 1.5mg/mL.
In such applications, the unit dose of the drug may be determined according to the effective amount of the subject/patient, and the unit dose of substance A may be 10-600mg, for example 10mg, 40mg, 100mg, 200mg, 250mg, 300mg, 400mg or 600mg.
In such applications, a single dose of the drug may be determined according to the actual therapeutic effect of the subject/patient each time the drug is administered, preferably the single dose of the drug is the mass ratio of the substance a to the subject/patient, which may be 1.8-30mg/kg, preferably 5-15mg/kg, for example 5mg/kg or 15mg/kg.
In such applications, the daily dose of the drug may be determined according to the actual therapeutic effect of the subject/patient each time the drug is administered, preferably the daily dose of the drug is the mass ratio of the substance a to the subject/patient, which may be 1.8-120mg/kg, preferably 10-30mg/kg, for example 10mg/kg or 30mg/kg.
In the application, the mass fraction of the compound shown as the formula I in the medicine is 5-80%, preferably 5-50%.
The invention also provides a pharmaceutical composition comprising substance a and a pharmaceutically acceptable carrier; the substance A is a compound shown in a formula I or pharmaceutically acceptable salt thereof;
the mass fraction of the compound shown in the formula I is 5-80%.
In the pharmaceutical composition, the mass fraction of the compound shown as the formula I can be 5-50%.
The invention also provides application of the pharmaceutical composition in preparing medicines for treating and/or preventing intracranial tumors.
Preferably, the intracranial tumor is a ROS1 fused intracranial tumor.
Preferably, the intracranial tumor is a glioma and/or a non-small cell brain metastasis, e.g., ROS1 fused glioma or ROS1 fused non-small cell brain metastasis.
The present invention also provides a method of treating and/or preventing an intracranial tumor, the method comprising: administering to the subject/patient a therapeutically effective amount of substance a or a drug comprising substance a and a pharmaceutically acceptable carrier; the substance A is a compound shown in a formula I or pharmaceutically acceptable salt thereof;
in the method, the intracranial tumor can be a glioma and/or a non-small cell brain metastasis, such as ROS1 fused glioma or ROS1 fused non-small cell brain metastasis.
In the method, the intracranial tumor can be a ROS1 fused intracranial tumor.
In the method, the pharmaceutically acceptable carrier may be a conventional carrier in the art.
In the method, the frequency of administration of the drug may be 1, 2, or 3 times per day.
In the method, the medicament may be administered orally.
In the method, the dosage form of the drug may be a conventional dosage form in the art.
In the method, the concentration of the compound shown as the formula I in the medicine can be 0.5-1.5mg/mL; preferably 0.5mg/mL or 1.5mg/mL.
In the method, the unit dose of the drug may be determined according to the effective amount of the subject/patient, and the unit dose of the substance A may be 10 to 600mg, for example, 10mg, 40mg, 100mg, 200mg, 250mg, 300mg, 400mg or 600mg.
In the method, each time the drug is administered, a single dose of the drug may be determined according to the actual therapeutic effect of the subject/patient, preferably, the single dose of the drug is a mass ratio of the substance a to the subject/patient, which may be 1.8-30mg/kg, preferably 5-15mg/kg, for example 5mg/kg or 15mg/kg.
In the method, the daily dose of the drug may be determined according to the actual therapeutic effect of the subject/patient each time the drug is administered, and preferably, the daily dose of the drug is the mass ratio of the substance a to the subject/patient, which may be 1.8 to 120mg/kg, preferably 10 to 30mg/kg, for example 10mg/kg or 30mg/kg.
The following terms and phrases used herein are intended to have the following meanings unless otherwise indicated. A particular term or phrase, unless otherwise specifically defined, should not be construed as being ambiguous or otherwise clear, but rather should be construed in a generic sense. When trade names are presented herein, it is intended to refer to their corresponding commercial products or active ingredients thereof.
The term "pharmaceutically acceptable" as used herein is intended to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium representative of a carrier capable of delivering an effective amount of the active agents of the present invention, which does not interfere with the biological activity of the active agents and which does not have toxic or side effects to the host or patient, including water, oils, vegetables and minerals, cream bases, lotion bases, ointment bases, and the like. Such matrices include suspending agents, viscosity enhancers, transdermal enhancers, and the like. Their formulations are well known to those skilled in the cosmetic or topical pharmaceutical arts. For further information on the carrier, reference may be made to Remington, the Science and Practice of Pharmacy,21 st Ed.,Lippincott,Williams&Wilkins (2005), the contents of which are incorporated herein by reference.
The term "treatment" refers to therapeutic therapy. When specific conditions are involved, treatment refers to: (1) alleviating a disease or one or more biological manifestations of a disorder, (2) interfering with (a) one or more points in a biological cascade that results in or causes a disorder or (b) one or more biological manifestations of a disorder, (3) ameliorating one or more symptoms, effects, or side effects associated with a disorder, or one or more symptoms, effects, or side effects associated with a disorder or treatment thereof, or (4) slowing the progression of a disorder or one or more biological manifestations of a disorder.
The term "preventing" refers to a reduced risk of acquiring or developing a disease or disorder.
The term "therapeutically effective amount" refers to an amount of a compound that is sufficient to effectively treat a disease or disorder described herein when administered to a patient. The "therapeutically effective amount" will vary depending on the compound, the condition and severity thereof, and the age of the patient to be treated, but can be adjusted as desired by one of ordinary skill in the art.
The term "patient" refers to any animal, preferably a mammal, most preferably a human, that is about to or has received administration of the compound according to embodiments of the present invention. The term "mammal" includes any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., with humans being preferred.
The above preferred conditions can be arbitrarily combined on the basis of not deviating from the common knowledge in the art, and thus, each preferred embodiment of the present invention can be obtained.
The reagents and materials used in the present invention are commercially available.
The invention has the positive progress effects that:
the compounds of the present invention are capable of treating and/or preventing intracranial tumors. Further, the compounds of the present invention are highly safe for the treatment and/or prevention of intracranial tumors.
Drawings
FIG. 1 is a graph showing survival during in vivo efficacy testing in mice according to example 1;
FIG. 2 is a graph showing the percentage change in body weight of mice during the in vivo efficacy test of mice in example 1.
Detailed Description
The invention is further illustrated by means of the following examples, which are not intended to limit the scope of the invention. The experimental methods, in which specific conditions are not noted in the following examples, were selected according to conventional methods and conditions, or according to the commercial specifications.
Test of the efficacy of the Compounds of example 1 in mice
The purpose of the experiment is as follows: the antitumor effect of the test agent on BaF3-GOPC-ROS1 cells in situ in the brain of Balb/c nude mice was evaluated, and the effect on the survival of the mice was studied.
Experimental materials: DMSO (purchased from Sigma), FBS (purchased from GIBCO), PRMI1640 (purchased from GIBCO), trypsin (purchased from GIBCO).
Experimental model: baF3-GOPC-ROS1 cells in vivo model of the intracranial brain in Balb/c nude mice.
The experimental method comprises the following steps:
cell culture: in vitro monolayer culture of cells under the conditions of adding 10% fetal bovine serum, 100U/mL penicillin and 100ug/mL streptomycin in RPMI1640 medium, 37deg.C, 5% CO 2 Culturing under 95% relative humidity, digesting and passaging twice a week with pancreatin, and when the cells are in logarithmic growth phase, digesting the cells for inoculation.
Experimental animals: BALB/c nude mice (Beijing Fukang Biotechnology Co., ltd.) were female, 6-8 weeks (the week age of mice at the time of tumor cell inoculation), and had a weight of 18-20g, for a total of 32.
Tumor inoculation: the treated cells were concentrated at a concentration of 2.5X10 7 cell/mL BAF3-GOPC-ROS1 cell suspension 0.2mL, placing on ice, blowing to uniformity, fixing the mice on a mouse brain stereotactic apparatus, inoculating 2 μl cell suspension, 5×10 with microinjector 4 Cell-
Only. The treatment for post-group dosing was as follows in table 1, with random grouping after the seventh day of inoculation.
Table 1 dosing of mice
Remarks:
a solvent: 10% DMSO (DMSO volume percent of volume of solution) +10% solutol (polyethylene glycol-15 hydroxystearate volume percent of volume of solution) +80% water;
experimental results:
1) Compound i had an average median survival of greater than 49 days at doses of 5mg/kg and 15mg/kg, both significantly prolonged median survival in mice (p=0.032 and p=0.007) compared to the control group.
2)TPX-0005The mean median survival of the group was 45 days, with a trend to extend median survival in mice compared to the solvent control group, but not statistically significant (0.177). In addition, median survival in mice treated with Compound I was longer than in mice treated with TPX-0005, and the median survival for mice in each of the treatment group and the solvent control group is shown in Table 2.
3) At the end of dosing, mice body weight significantly decreased after TPX-0005 treatment compared to control, with a mean percent body weight change of-11.48% (P < 0.05), whereas mice treated with compound i (5 mg/kg and 15 mg/kg) had little body weight decrease, with mean percent body weight change of-4.99% (p=0.254) and-0.81% (P < 0.05), respectively. Compound i significantly prolonged the minimum survival and increased survival of mice at the end of the experiment compared to TPX-0005. As shown in table 2.
TABLE 2 median survival in mice
TABLE 3 rate of weight change in mice
Conclusion of experiment: the tested compound I has a remarkable inhibition effect on the growth of BAF3-GOPC-ROS1 intracranial brain in-situ transplantation tumor of a nude mouse, and remarkably prolongs the survival median period of the mouse. In this brain in situ mouse model, compound I has a better cancer inhibition trend than TPX-0005.
Compound i showed little decrease in body weight from the percent change in body weight of mice at two doses (5 mg/kg and 15 mg/kg); whereas the control compound TPX-0005 showed a gradual decrease in body weight and intolerance trend at the dose of 3 mg/kg. The results showed that compound I was safer than TPX-0005 (3 mg/kg). As shown in fig. 2.
From the shortest survival time and the number of surviving mice at the end of the experiment, compound i survived significantly longer than the solvent control and TPX-005 at both doses (5 mg/kg and 15 mg/kg), and the survival rate of mice at the end of the experiment was much higher than that of the control, as shown in fig. 1. The compound I has obvious inhibition effect on the growth of BAF3-GOPC-ROS1 intracranial brain in-situ transplantation tumor of nude mice.
Example 2
One lung adenocarcinoma patient with clear pathology diagnosis, NGS detection was clear as ROS1 gene fusion mutation. The patient is treated for drug resistance through multiple lines in the past, such as first-line Ecotinib, second-line Kzotinib, three-line-PEMEITIACESS combined carboplatin and four-line succinic acid compound critinib, wherein the Kzotinib and the succinic acid compound critinib are inhibitors for targeting ROS 1. Subjects were enrolled in clinical trials of a phase I clinical study of safety, tolerability, pharmacokinetic profile and primary efficacy of compound I in ROS1 gene fusion positive locally advanced/metastatic solid tumor patients after multi-line treatment of drug resistance. The tests of vital signs, physical examination, ECOG physical scores, infectious disease markers, blood routine, urine routine, blood coagulation function, liver function, kidney function, electrolyte, fasting blood glucose, blood fat, 12-lead electrocardiogram and the like are carried out in the baseline period, and the conditions of group inclusion are met. Before group entry, imaging to determine the position and the size of a target focus, wherein the diameter of the target focus is 15mm (1) for the right upper lung and 15.5mm for the left upper lung; (3) Lymph node (right neck), diameter 25.4mm, (4) lymph node (anterior superior vena cava), diameter 28.5mm, (5) brain (left frontal lobe), 13.6mm, total diameter 97.8mm.
Following single drug treatment of the subject with compound i, the specific dosing regimen is as follows: compound I tablet is orally administered orally on an empty stomach, 1 time a day, 300mg each time, and continuously. And the medicine is subjected to vital sign, physical examination, blood routine examination, urine routine examination, liver function, kidney function, electrolyte, fasting blood glucose, blood fat, 12-lead electrocardiogram and other examinations every week (within the first month after taking medicine) or every two weeks (after the first month after taking medicine), and no serious side effects occur during taking medicine; imaging tumor evaluation after single drug treatment of compound I, (1) upper right lung with diameter of 8.5mm, (2) upper left lung with diameter of 10.5mm; (3) Lymph node (right neck), diameter 19.9mm, (4) lymph node (anterior superior vena cava), diameter 26.5mm, (5) brain (left frontal lobe), 8.7mm, total diameter 74.1mm. Compared with the baseline, the overall diameter of the tumor is reduced by 24.2 percent, and the overall diameter of the brain tumor metastasis is reduced by 36 percent.
The study shows that the compound I can reduce the overall tumor volume of patients suffering from brain metastatic lung adenocarcinoma, in particular the brain. Furthermore, the patient did not show any serious side effects. Taken together, the treatment of compound i has clinical benefit (demonstrated efficacy and high safety) for lung adenocarcinoma patients with brain-transferred ROS1 fusion mutations.
While particular embodiments of the present invention have been described above, it will be appreciated by those skilled in the art that these are merely illustrative, and that many changes and modifications may be made to these embodiments without departing from the principles and spirit of the invention. Accordingly, the scope of the invention is defined by the appended claims.
Claims (10)
1. The application of a substance A in preparing medicines is characterized in that the substance A is a compound shown as a formula I or pharmaceutically acceptable salt thereof; the medicine is used for treating and/or preventing intracranial tumor;
2. the use according to claim 1, wherein,
the intracranial tumor is ROS1 fusion intracranial tumor,
and/or, the intracranial tumor is a glioma and/or a non-small cell brain metastasis.
3. The use according to claim 2, wherein,
the intracranial tumor is ROS1 fused glioma or ROS1 fused non-small cell brain metastasis.
4. The application of claim 1, wherein the application satisfies one or more of the following conditions:
(1) the medicament comprises a substance A and a pharmaceutically acceptable carrier;
(2) the frequency of administration of the drug is 1, 2 or 3 times/day;
(3) the medicament is administered orally;
(4) the unit dose of the substance A is 10-600mg;
and (5) the concentration of the compound shown as the formula I in the medicine is 0.5-1.5mg/mL.
5. The application of claim 4, wherein the application satisfies one or both of the following conditions:
(1) the unit dose of the substance A is 10mg, 40mg, 100mg, 200mg, 250mg, 300mg, 400mg or 600mg;
and (2) the concentration of the compound shown as the formula I in the medicine is 0.5mg/mL or 1.5mg/mL.
6. The use according to any one of claims 1-5, wherein in the use,
a single dose of the medicament is a mass ratio of the substance a to the subject/patient of 1.8-30mg/kg, preferably 5-15mg/kg, for example 5mg/kg or 15mg/kg;
preferably, in said application, the daily dose of said medicament is the mass ratio of said substance a to the subject/patient, said mass ratio being between 1.8 and 120mg/kg, preferably between 10 and 30mg/kg, for example 10mg/kg or 30mg/kg.
7. The use according to any one of claims 1 to 5, wherein the compound of formula i represents 5 to 80%, preferably 5 to 50% by mass of the medicament.
8. A pharmaceutical composition comprising substance a and a pharmaceutically acceptable carrier; the substance A is a compound shown in a formula I or pharmaceutically acceptable salt thereof;
the mass fraction of the compound shown in the formula I is 5-80%.
9. The pharmaceutical composition according to claim 8, wherein the mass fraction of the compound of formula i is 5-50%.
10. The use of a pharmaceutical composition according to claim 8 for the preparation of a medicament for the treatment and/or prophylaxis of intracranial tumours,
preferably, the intracranial tumor is a ROS1 fused intracranial tumor;
and/or, the intracranial tumor is a glioma and/or a non-small cell brain metastasis, such as ROS1 fused glioma or ROS1 fused non-small cell brain metastasis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210861773 | 2022-07-20 | ||
| CN2022108617733 | 2022-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117427079A true CN117427079A (en) | 2024-01-23 |
Family
ID=89554261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310893963.8A Pending CN117427079A (en) | 2022-07-20 | 2023-07-19 | Use of cyano-substituted macrocyclic compounds |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117427079A (en) |
| WO (1) | WO2024017305A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016344058A1 (en) * | 2015-10-26 | 2018-05-17 | Array Biopharma Inc. | Point mutations in Trk inhibitor-resistant cancer and methods relating to the same |
| CN109575025B (en) * | 2018-01-23 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | Macrocyclic compounds of the substituted pyrazolo [1,5-a ] pyrimidines |
| CN111788205B (en) * | 2018-02-28 | 2022-04-26 | 先声药业有限公司 | Pyrazolopyrimidine derivative and use thereof |
| CN110577549A (en) * | 2018-06-08 | 2019-12-17 | 焦玉奇 | Macrocyclic compounds |
| CN112110938B (en) * | 2019-06-21 | 2021-11-09 | 成都海博为药业有限公司 | Compound as protein kinase inhibitor and preparation method and application thereof |
| CN114761407A (en) * | 2019-11-18 | 2022-07-15 | 广州嘉越医药科技有限公司 | Compound serving as highly selective ROS1 inhibitor and application thereof |
-
2023
- 2023-07-19 CN CN202310893963.8A patent/CN117427079A/en active Pending
- 2023-07-19 WO PCT/CN2023/108205 patent/WO2024017305A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024017305A1 (en) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240041864A1 (en) | Methods for treating soft tissue sarcoma | |
| Da Fonseca et al. | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas | |
| ES2586843T3 (en) | Treatment of disorders related to BDNF using laquinimod | |
| RU2737508C2 (en) | Methods of influencing transcription control in super-enhancer areas | |
| JP6837486B2 (en) | How to Prevent and / or Treat Age-Related Cognitive Disorders and Neuroinflammation | |
| US20090018142A9 (en) | Use of phosphatases to treat tumors overexpressing N-CoR | |
| WO2007092414A2 (en) | Use of phosphatases to treat tumors overexpressing n-cor | |
| EA032345B1 (en) | Method of treating cancer using coenzyme q10 | |
| JP2004515453A (en) | Compositions and methods for protecting cells while subjecting cancer to chemotherapy and radiation therapy | |
| KR20120050473A (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| KR20180014834A (en) | Compositions and uses containing carboplatin | |
| Baird et al. | Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors | |
| CN110934879B (en) | Anti-aging drug D/A targeting aged cells in tissue microenvironment and application thereof | |
| CN116761593A (en) | Application of honokiol in preparation of medicament for treating meningioma | |
| ES2702578T3 (en) | Treatment of chronic dermal inflammation with norketotifen | |
| He et al. | Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats | |
| WO2020192506A1 (en) | Chiauranib for treatment of small cell lung cancer | |
| EA001325B1 (en) | Methods ot treating or preventing interstitial cystitis | |
| CN117427079A (en) | Use of cyano-substituted macrocyclic compounds | |
| US20200138744A1 (en) | Methods of treating pancreatic cancer using coenzyme q10 | |
| CN113329749A (en) | Combination therapy for the treatment of uveal melanoma | |
| US20110182973A1 (en) | Polymerase inhibitors and the use thereof for the treatment of tumors | |
| CN112274509B (en) | Application of xidabenamine and BCL2 inhibitor in double-expression B cell lymphoma | |
| US20190029951A1 (en) | Extended release formulations of veliparib for the treatment of cancer | |
| US20150209303A1 (en) | Zeaxanthin for tumor treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |